Indication
Non-Transfusion-dependent Alpha-Thalassemia
1 clinical trial
1 product
Product
MitapivatClinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)Status: Active (not recruiting), Estimated PCD: 2023-11-13